These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7387820)

  • 1. Cefoxitin: intravenous pharmacokinetics and intramuscular bioavailability in kwashiorkor.
    Buchanan N; Mithal Y; Witcomb M
    Br J Clin Pharmacol; 1980 Jun; 9(6):623-7. PubMed ID: 7387820
    [No Abstract]   [Full Text] [Related]  

  • 2. Intramuscular tobramycin administration in kwashiorkor.
    Buchanan N; Eyberg C
    S Afr Med J; 1978 Feb; 53(8):273-4. PubMed ID: 653530
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin.
    Sonneville PF; Albert KS; Skeggs H; Gentner H; Kwan KC; Martin CM
    Eur J Clin Pharmacol; 1977 Dec; 12(4):273-9. PubMed ID: 590313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cefoxitin administered intramuscularly to rabbits with experimentally-induced renal impairment.
    Garcia MJ; Dominguez-Gil AA; Cepeda M; Dominguez-Gil A
    Biopharm Drug Dispos; 1981; 2(3):205-13. PubMed ID: 7295878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefoxitin serum and uterine concentrations following a two-gram intramuscular dose.
    Hemsell DL; Birkett I; Reveley L; Bland JA
    Obstet Gynecol; 1982 Feb; 59(2):149-52. PubMed ID: 7078858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmammary passage of cefoxitin: additional results.
    Dresse A; Lambotte R; Dubois M; Delapierre D; Kramp R
    J Clin Pharmacol; 1983 Oct; 23(10):438-40. PubMed ID: 6643697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Laboratory and clinical studies of cefoxitin in pediatric infections (author's transl)].
    Nishikawa K; Aso K; Miyachi Y; Ogawa A; Kuno K; Kondo K
    Jpn J Antibiot; 1981 Mar; 34(3):279-86. PubMed ID: 7289021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefoxitin after intravenous and intramuscular administration to cats.
    Albarellos GA; Montoya L; Quaine PC; Lupi MP; Landoni MF
    J Vet Pharmacol Ther; 2010 Dec; 33(6):619-21. PubMed ID: 21108508
    [No Abstract]   [Full Text] [Related]  

  • 9. [Some experiences in the field of pediatrics with cefoxitin treatment by intravenous injections (author's transl)].
    Hirama Y; Iwasaki A; Suzuki H; Nakazawa S; Narita A; Niino K; Sato H; Nakazawa S; Chikaoka H; Oka S
    Jpn J Antibiot; 1981 Mar; 34(3):244-56. PubMed ID: 7289019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Laboratory and clinical studies of cefoxitin in pediatric field (author's transl)].
    Nishimura T; Hiromatsu K; Tabuki K; Takashima T
    Jpn J Antibiot; 1981 Mar; 34(3):310-7. PubMed ID: 7289024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical safety and tolerance of cefoxitin sodium: an overview.
    van Winzum C
    J Antimicrob Chemother; 1978 Jul; 4(B):91-104. PubMed ID: 357400
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.
    Kokki H; Rasanen I; Reinikainen M; Suhonen P; Vanamo K; Ojanperä I
    Clin Pharmacokinet; 2004; 43(9):613-22. PubMed ID: 15217304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous fructose disappearance in protein calorie malnutrition.
    Becker DJ; Pimstone BL
    S Afr Med J; 1974 Nov; 48(54):2243-4. PubMed ID: 4215159
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical experience with cefoxitin sodium in extensive trials.
    Mogabgab WJ; Alvarez S; Beville RB
    J Antimicrob Chemother; 1978 Jul; 4(B):215-8. PubMed ID: 357390
    [No Abstract]   [Full Text] [Related]  

  • 15. Patterns of insulin response to glucose in protein-calorie malnutrition.
    Becker DJ; Pimstone BL; Hansen JD; MacHutchon B; Drysdale A
    Am J Clin Nutr; 1972 May; 25(5):499-505. PubMed ID: 4623275
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioavailability and pharmacokinetics of cefoxitin sodium.
    Schrogie JJ; Davies RO; Yeh KC; Rogers D; Holmes GI; Skeggs H; Martin CM
    J Antimicrob Chemother; 1978 Jul; 4(B):69-78. PubMed ID: 99418
    [No Abstract]   [Full Text] [Related]  

  • 17. [Laboratory and clinical studies on cefoxitin in pediatric field (author's transl)].
    Iwai N; Sasaki A; Taneda Y; Osuga T; Inokuma K
    Jpn J Antibiot; 1981 Mar; 34(3):287-304. PubMed ID: 7289022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical experience with cefoxitin in bacterial infections of children (author's transl)].
    Yuasa Y; Ichioka T; Sekiguchi T; Miyao M; Toi C; Hayashi K; Yamashita K; Tanaka H
    Jpn J Antibiot; 1981 Mar; 34(3):359-66. PubMed ID: 7289028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A clinical study of cefoxitin in children (author's transl)].
    Yanagisawa K; Hoshina H; Ichihashi H
    Jpn J Antibiot; 1981 Mar; 34(3):305-9. PubMed ID: 7289023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of cefoxitin, a new semisynthetic cephamycin.
    Little PJ; Peddie BA
    N Z Med J; 1978 Jul; 88(616):46-9. PubMed ID: 279853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.